Page last updated: 2024-10-17

creatine and Atrophy

creatine has been researched along with Atrophy in 61 studies

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
"The X-linked creatine transporter deficiency (CRTD) caused by an SLC6A8 mutation represents the second most common cause of X-linked intellectual disability."7.85Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity. ( Dörr, HG; Heussinger, N; Mennecke, A; Saake, M; Trollmann, R, 2017)
" We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3."7.74Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008)
"The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months."7.72N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003)
"Gyrate atrophy of the choroid and retina is a disease characterized by progressive constriction of visual fields, a 10-fold to 20-fold elevation in plasma ornithine, and depressed activity of L-ornithine:2 oxoacid aminotransferase."7.66Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. ( Rapola, J; Simell, O; Sipilä, I; Vannas, A, 1981)
"Patients with gyrate atrophy of the choroid and retina have 10- to 20-fold increased ornithine concentrations in body fluids and significantly reduced activity of ornithine aminotransferase in lymphocytes and cultured fibroblasts."7.66Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. ( Arjomaa, P; Simell, O; Sipilä, I, 1980)
" Neuroimaging measures were central (ventricular) cerebral atrophy, lesion volume, and ratios of N-acetyl aspartate (NAA) to both creatine and choline."5.10Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. ( Christodoulou, C; Huang, W; Krupp, LB; Li, L; Li, X; Liang, Z; MacAllister, WS; Melville, P; Morgan, T; Peyster, R; Roche, P; Roque, C; Scherl, WF; Tudorica, LA, 2003)
"The X-linked creatine transporter deficiency (CRTD) caused by an SLC6A8 mutation represents the second most common cause of X-linked intellectual disability."3.85Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity. ( Dörr, HG; Heussinger, N; Mennecke, A; Saake, M; Trollmann, R, 2017)
" We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3."3.74Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008)
"Mesial temporal lobe epilepsy (mTLE) is characterized by hippocampal atrophy, decreased N-acetyl-aspartate, and a low N-acetyl-aspartate/total creatine ratio, often attributed to neuron loss and gliosis."3.72N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus. ( Errante, LD; Kim, JH; Petroff, OA; Spencer, DD, 2003)
"The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months."3.72N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003)
"To assess whether differences in cerebral atrophy and white matter lesions or in the presence of lactate and lipid signals can explain the observed differences in brain choline, creatine, and N-acetylaspartate levels between healthy elderly women and men."3.71Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites. ( Achten, E; Breteler, MM; De Groot, JC; De Leeuw, FE; Den Heijer, T; Heijboer, RJ; Hofman, A; Oudkerk, M; Sijens, PE, 2001)
" Thalamic and white matter metabolite concentrations (myo-inositol (mI), choline-containing compounds (Cho), total creatine (Cr) and N-acetylaspartate (NAA)) were estimated and corrected for atrophy (CSF) and gray and white matter contributions (GM, WM) by use of image-based voxel segmentation."3.71Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. ( Auer, DP; Bronisch, T; Grabner, A; Heidenreich, JO; Wetter, TC; Wilke, M, 2001)
"The N-acetylaspartate-to-creatine/phosphocreatine ratio was smaller in those patients with significant cerebral atrophy (1."3.69Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. ( Griffey, RH; Hart, BL; Haseler, LJ; Matwiyoff, NA; Sibbitt, RR; Sibbitt, WL, 1994)
"The aim of the study is to determine whether biochemical abnormalities, such as lipid, creatine and choline metabolites, are observed in the more distal muscles of polymyositis (PM) and dermatomyositis (DM) patients."3.69In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: a preliminary study. ( Chung, YL; Howlett, DC; Salisbury, JR; Scott, DL; Simmons, A; Smith, EC; Wassif, WS; Williams, SC, 1997)
" This study assessed urinary creatine excretion as a marker for testicular atrophy."3.68An investigation of urinary creatine excretion as a potential marker for testicular damage. ( le Net, JL; Nahas, K; Provost, JP; Tomaszewski, KE, 1993)
"Gyrate atrophy of the choroid and retina is a disease characterized by progressive constriction of visual fields, a 10-fold to 20-fold elevation in plasma ornithine, and depressed activity of L-ornithine:2 oxoacid aminotransferase."3.66Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. ( Rapola, J; Simell, O; Sipilä, I; Vannas, A, 1981)
"Patients with gyrate atrophy of the choroid and retina have 10- to 20-fold increased ornithine concentrations in body fluids and significantly reduced activity of ornithine aminotransferase in lymphocytes and cultured fibroblasts."3.66Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. ( Arjomaa, P; Simell, O; Sipilä, I, 1980)
"Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic event(s)."2.58Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder. ( Mountford, C; Quadrelli, S; Ramadan, S, 2018)
"Despite the high incidence of major depressive disorder (MDD) in females, the detailed neurobiology mechanism remains not fully understood."1.48Left fimbria atrophy is associated with hippocampal metabolism in female major depressive disorder patients. ( Cecilio Baro, C; Li, Y; Meng, Z; Tang, Y; Xu, J; Zhang, X, 2018)
"Hypertension is associated with cognitive decline in elderly persons."1.36Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes. ( Antequera, M; Antúnez, C; Campoy, G; Carrillo, A; Fuentes, LJ; García Santos, JM; García-Sevilla, J; Ortega, G; Torres del Río, S; Vidal, JB, 2010)
"Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency."1.35Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008)
"Chronic alcohol abuse results in morphological, metabolic, and functional brain damage which may, to some extent, be reversible with early effects upon abstinence."1.34Manifestations of early brain recovery associated with abstinence from alcoholism. ( Bartsch, AJ; Bendszus, M; Biller, A; De Stefano, N; Homola, G; Jenkinson, M; Smith, SM; Solymosi, L; Weijers, HG; Wiesbeck, GA, 2007)
"PEHO syndrome is a rare symptom complex of severe progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy."1.33Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome. ( Boltshauser, E; Huisman, TA; Klein, A; Straube, T; Werner, B, 2006)
"Eleven IDDM patients with no history of severe hypoglycemia (group A) were compared with 11 IDDM patients who had a history of five or more episodes of severe hypoglycemia (group B)."1.30Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. ( Best, JJ; Deary, IJ; Frier, BM; Perros, P; Sellar, RJ, 1997)
"Patients with AIDS had more signs of neurological dysfunction, poorer performance on a neuropsychological test battery, were more likely to have an abnormal EEG, and to have abnormalities on MRI."1.30Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. ( Carter, S; Fowler, CJ; Hall-Craggs, MA; Harrison, MJ; Kendall, BE; Lunn, S; Miller, R; Newman, SP; Paley, M; Sweeney, B; Wilkinson, I; Williams, I, 1998)
"Four grades of demyelination and three grades of cerebral atrophy were distinguished by magnetic resonance imaging criteria."1.281H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders. ( den Hollander, JA; Luyten, PR; Nauta, JJ; Valk, J; van der Grond, J; van der Knaap, MS, 1992)
"The effect of implantation of Ehrlich ascites tumor (EAT) cells on creatine distribution was investigated."1.28Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed beta-guanidinopropionic acid. ( Inoue, N; Ishine, S; Ohira, Y; Yunoki, K, 1991)

Research

Studies (61)

TimeframeStudies, this research(%)All Research%
pre-19908 (13.11)18.7374
1990's16 (26.23)18.2507
2000's27 (44.26)29.6817
2010's10 (16.39)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blicher, JU1
Eskildsen, SF1
Stærmose, TG1
Møller, AT1
Figlewski, K1
Near, J1
Bodini, B1
Branzoli, F1
Poirion, E1
García-Lorenzo, D1
Didier, M1
Maillart, E1
Socha, J1
Bera, G1
Lubetzki, C1
Ronen, I1
Lehericy, S1
Stankoff, B1
Crespo-Eguilaz, N1
Dominguez, PD1
Vaquero, M1
Narbona, J1
Quadrelli, S1
Mountford, C1
Ramadan, S1
Wang, W1
Sun, H1
Su, X1
Tan, Q1
Zhang, S1
Xia, C1
Li, L2
Kemp, GJ1
Yue, Q1
Gong, Q1
Xu, J1
Tang, Y1
Cecilio Baro, C1
Zhang, X1
Meng, Z1
Li, Y1
Rosas, HD1
Doros, G1
Gevorkian, S1
Malarick, K1
Reuter, M1
Coutu, JP1
Triggs, TD1
Wilkens, PJ1
Matson, W1
Salat, DH1
Hersch, SM2
Auriel, E1
Kliper, E1
Shenhar-Tsarfaty, S1
Molad, J1
Berliner, S1
Shapira, I1
Ben-Bashat, D1
Shopin, L1
Tene, O1
Rosenberg, GA1
Bornstein, NM1
Ben Assayag, E1
Heussinger, N1
Saake, M1
Mennecke, A1
Dörr, HG1
Trollmann, R1
Kantarci, K1
Weigand, SD1
Przybelski, SA1
Shiung, MM1
Whitwell, JL1
Negash, S1
Knopman, DS1
Boeve, BF1
O'Brien, PC1
Petersen, RC1
Jack, CR1
García Santos, JM1
Fuentes, LJ1
Vidal, JB1
Carrillo, A1
Antequera, M1
Campoy, G1
Antúnez, C1
Torres del Río, S1
García-Sevilla, J1
Ortega, G1
Sarchielli, P1
Presciutti, O1
Tarducci, R1
Gobbi, G1
Alberti, A1
Pelliccioli, GP1
Chiarini, P1
Gallai, V1
Gambini, A1
Falini, A1
Moiola, L1
Comi, G1
Scotti, G1
Petroff, OA1
Errante, LD1
Kim, JH1
Spencer, DD1
Christodoulou, C1
Krupp, LB1
Liang, Z1
Huang, W1
Melville, P1
Roque, C1
Scherl, WF1
Morgan, T1
MacAllister, WS1
Tudorica, LA1
Li, X1
Roche, P1
Peyster, R1
Konaka, K1
Ueda, H1
Li, JY1
Matsumoto, M1
Sakoda, S1
Yanagihara, T2
Tyler, TF1
Nicholas, SJ1
Hershman, EB1
Glace, BW1
Mullaney, MJ1
McHugh, MP1
Lodi, R1
Tonon, C1
Vignatelli, L1
Iotti, S1
Montagna, P1
Barbiroli, B1
Plazzi, G1
Briellmann, RS1
Wellard, RM1
Jackson, GD1
Inglese, M1
Nusbaum, AO1
Pastores, GM1
Gianutsos, J1
Kolodny, EH1
Gonen, O1
Kin, T1
Hirano, M1
Taoka, T1
Takamure, M1
Furiya, Y1
Kichikawa, K1
Ueno, S1
Huisman, TA1
Klein, A1
Werner, B1
Straube, T1
Boltshauser, E1
Lantz, G1
Seeck, M1
Lazeyras, F1
Bartsch, AJ1
Homola, G1
Biller, A1
Smith, SM1
Weijers, HG1
Wiesbeck, GA1
Jenkinson, M1
De Stefano, N2
Solymosi, L1
Bendszus, M1
Tebartz van Elst, L1
Ludaescher, P1
Thiel, T1
Büchert, M1
Hesslinger, B1
Bohus, M1
Rüsch, N1
Hennig, J1
Ebert, D1
Lieb, K1
Roc, AC1
Ances, BM1
Chawla, S1
Korczykowski, M1
Wolf, RL1
Kolson, DL1
Detre, JA1
Poptani, H1
Schubert, MI1
Kalisch, R1
Sotiropoulos, I1
Catania, C1
Sousa, N1
Almeida, OF1
Auer, DP2
Schuff, N3
Neylan, TC2
Fox-Bosetti, S1
Lenoci, M1
Samuelson, KW1
Studholme, C1
Kornak, J1
Marmar, CR2
Weiner, MW3
Güngör, S1
Akinci, A1
Firat, AK1
Tabel, Y1
Alkan, A1
Azevedo, D1
Tatsch, M1
Hototian, SR1
Bazzarella, MC1
Castro, CC1
Bottino, CM1
Sipilä, I4
Rapola, J2
Simell, O3
Vannas, A2
Arjomaa, P1
Davie, CA1
Wenning, GK1
Barker, GJ1
Tofts, PS1
Kendall, BE2
Quinn, N1
McDonald, WI1
Marsden, CD1
Miller, DH1
Sibbitt, WL1
Haseler, LJ1
Griffey, RH1
Hart, BL1
Sibbitt, RR1
Matwiyoff, NA1
Nahas, K1
le Net, JL1
Provost, JP1
Tomaszewski, KE1
Tedeschi, G1
Bertolino, A1
Massaquoi, SG1
Campbell, G1
Patronas, NJ1
Bonavita, S2
Barnett, AS1
Alger, JR1
Hallett, M1
Ende, GR1
Laxer, KD1
Knowlton, RC1
Matson, GB1
Fein, G1
Perros, P1
Deary, IJ1
Sellar, RJ1
Best, JJ1
Frier, BM1
Chung, YL1
Smith, EC1
Williams, SC1
Wassif, WS1
Salisbury, JR1
Simmons, A1
Howlett, DC1
Scott, DL1
Maeda, H1
Furune, S1
Nomura, K1
Kitou, O1
Ando, Y1
Negoro, T1
Watanabe, K1
van der Knaap, MS2
Bakker, HD1
Valk, J2
Harrison, MJ1
Newman, SP1
Hall-Craggs, MA1
Fowler, CJ1
Miller, R1
Paley, M1
Wilkinson, I1
Sweeney, B1
Lunn, S1
Carter, S1
Williams, I1
Akiguchi, I1
Nakano, S1
Shiino, A1
Kimura, R1
Inubushi, T1
Handa, J1
Nakamura, M2
Tanaka, M1
Oka, N1
Kimura, J1
Terakawa, H1
Abe, K1
Watanabe, Y1
Fujita, N1
Hirabuki, N1
Lundbom, N1
Barnett, A1
Patronas, N1
Rajapakse, J1
Di Chiro, G1
Li, LM1
Cendes, F1
Antel, SB1
Andermann, F1
Serles, W1
Dubeau, F1
Olivier, A1
Arnold, DL2
Ferrante, RJ1
Andreassen, OA1
Jenkins, BG1
Dedeoglu, A1
Kuemmerle, S1
Kubilus, JK1
Kaddurah-Daouk, R1
Beal, MF1
Narayanan, S1
Francis, GS1
Arnaoutelis, R1
Tartaglia, MC1
Antel, JP1
Matthews, PM1
Sijens, PE1
Den Heijer, T1
De Leeuw, FE1
De Groot, JC1
Achten, E1
Heijboer, RJ1
Hofman, A1
Breteler, MM1
Oudkerk, M1
Wilke, M1
Grabner, A1
Heidenreich, JO1
Bronisch, T1
Wetter, TC1
Hespel, P1
Op't Eijnde, B1
Van Leemputte, M1
Ursø, B1
Greenhaff, PL1
Labarque, V1
Dymarkowski, S1
Van Hecke, P1
Richter, EA1
Lenoci, MA1
Du, AT1
Weiss, DS1
Hofmann, WW1
Butte, J1
Leon, HA1
Wang, Z1
Bogdan, AR1
Zimmerman, RA1
Gusnard, DA1
Leigh, JS1
Ohene-Frempong, K1
van der Grond, J1
Luyten, PR1
den Hollander, JA1
Nauta, JJ1
Ohira, Y1
Ishine, S1
Inoue, N1
Yunoki, K1
Déli, E1
Somlyay, I1
Várnagy, L1
Vannas-Sulonen, K1
Suzuki, H1
Wegelius, O1
Pasternack, A1
Kuhlbäck, B1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans[NCT02729428]71 participants (Actual)Observational2016-04-30Completed
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426]Phase 3553 participants (Actual)Interventional2009-09-30Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.)
Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995]Phase 264 participants (Actual)Interventional2007-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

Reviews

2 reviews available for creatine and Atrophy

ArticleYear
Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder.
    Psychiatry research. Neuroimaging, 2018, 12-30, Volume: 282

    Topics: Aspartic Acid; Atrophy; Brain; Creatine; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Hippocampus

2018
Seizure-associated abnormalities in epilepsy: evidence from MR imaging.
    Epilepsia, 2005, Volume: 46, Issue:5

    Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Brain Edema; Choline; Creatine; Diffusion Magn

2005

Trials

5 trials available for creatine and Atrophy

ArticleYear
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.
    Neurology, 2014, Mar-11, Volume: 82, Issue:10

    Topics: Adult; Atrophy; Biomarkers; Brain; Cognition Disorders; Creatine; Cross-Over Studies; Diffusion Magn

2014
Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.
    Neurology, 2003, Jun-10, Volume: 60, Issue:11

    Topics: Adult; Aspartic Acid; Atrophy; Axons; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; Cre

2003
The effect of creatine supplementation on strength recovery after anterior cruciate ligament (ACL) reconstruction: a randomized, placebo-controlled, double-blind trial.
    The American journal of sports medicine, 2004, Volume: 32, Issue:2

    Topics: Administration, Oral; Adult; Anterior Cruciate Ligament; Anterior Cruciate Ligament Injuries; Atroph

2004
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
    Dementia and geriatric cognitive disorders, 2008, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord

2008
Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.
    The Journal of physiology, 2001, Oct-15, Volume: 536, Issue:Pt 2

    Topics: Adenosine Triphosphate; Administration, Oral; Adult; Atrophy; Body Weight; Creatine; DNA-Binding Pro

2001

Other Studies

54 other studies available for creatine and Atrophy

ArticleYear
Short echo-time Magnetic Resonance Spectroscopy in ALS, simultaneous quantification of glutamate and GABA at 3 T.
    Scientific reports, 2019, 11-26, Volume: 9, Issue:1

    Topics: Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Choline; Creatine; Disease Progression;

2019
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2018, Volume: 24, Issue:3

    Topics: Adult; Aspartic Acid; Atrophy; Creatine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Fe

2018
[Developmental amnesia and early brain damage: neuropsychology and neuroimaging].
    Revista de neurologia, 2018, Mar-01, Volume: 66, Issue:S01

    Topics: Adolescent; Amnesia; Aspartic Acid; Atrophy; Cerebral Palsy; Child; Choline; Creatine; Female; Fetal

2018
Increased right amygdala metabolite concentrations in the absence of atrophy in children and adolescents with PTSD.
    European child & adolescent psychiatry, 2019, Volume: 28, Issue:6

    Topics: Adolescent; Amygdala; Aspartic Acid; Atrophy; Biomarkers; Child; Choline; Creatine; Cross-Sectional

2019
Left fimbria atrophy is associated with hippocampal metabolism in female major depressive disorder patients.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2018, Volume: 2018

    Topics: Atrophy; Creatine; Depressive Disorder, Major; Female; Hippocampus; Humans; Magnetic Resonance Imagi

2018
Impaired renal function is associated with brain atrophy and poststroke cognitive decline.
    Neurology, 2016, 05-24, Volume: 86, Issue:21

    Topics: Aged; Atrophy; Brain; Brain Ischemia; Cognitive Dysfunction; Creatine; Diffusion Tensor Imaging; Fem

2016
Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity.
    Pediatric neurology, 2017, Volume: 67

    Topics: Adolescent; Atrophy; Brain Diseases, Metabolic, Inborn; Child; Creatine; Female; Genotype; Humans; I

2017
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS.
    Neurology, 2009, Apr-28, Volume: 72, Issue:17

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Biomarkers; Brain; Cerebrovascular Disorders; Cogni

2009
Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:1

    Topics: Aged; Antihypertensive Agents; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Cerebral Hemorrhage;

2010
Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.
    Journal of neurology, 2002, Volume: 249, Issue:7

    Topics: Adult; Aspartic Acid; Atrophy; Creatine; Disease Progression; Female; Humans; Magnetic Resonance Spe

2002
Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study.
    AJNR. American journal of neuroradiology, 2003, Volume: 24, Issue:2

    Topics: Alcohol-Related Disorders; Atrophy; Choline; Corpus Callosum; Creatine; Demyelinating Diseases; Huma

2003
N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus.
    Neurology, 2003, May-27, Volume: 60, Issue:10

    Topics: Adolescent; Adult; Anterior Temporal Lobectomy; Aspartic Acid; Atrophy; Creatine; Epilepsy, Temporal

2003
N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2003, Volume: 23, Issue:6

    Topics: Animals; Aspartic Acid; Astrocytes; Atrophy; Cell Count; Common Variable Immunodeficiency; Creatine;

2003
In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients.
    Neurology, 2004, Oct-26, Volume: 63, Issue:8

    Topics: Adolescent; Adult; Aged; Aspartic Acid; Atrophy; Cataplexy; Creatine; Female; Humans; Hypothalamus;

2004
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.
    AJNR. American journal of neuroradiology, 2005, Volume: 26, Issue:8

    Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Case-Control Studies; Cerebellum; Creatine; Female; Gan

2005
Proton MR spectroscopy of adult-onset dentatorubral-pallidoluysian atrophy.
    Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2005, Volume: 4, Issue:3

    Topics: Aged; Aspartic Acid; Atrophy; Basal Ganglia Diseases; Case-Control Studies; Choline; Creatine; Denta

2005
Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:7

    Topics: Aspartic Acid; Atrophy; Brain Diseases; Brain Edema; Cerebellum; Child; Choline; Creatine; Diffusion

2006
Extent of preoperative abnormalities and focus lateralization predict postoperative normalization of contralateral 1H-magnetic resonance spectroscopy metabolite levels in patients with temporal lobe epilepsy.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:8

    Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Electroencephalography; Energ

2006
Manifestations of early brain recovery associated with abstinence from alcoholism.
    Brain : a journal of neurology, 2007, Volume: 130, Issue:Pt 1

    Topics: Adult; Alcoholism; Aspartic Acid; Atrophy; Attention; Brain; Brain Chemistry; Cerebellum; Choline; C

2007
Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder.
    Neuroscience letters, 2007, Apr-24, Volume: 417, Issue:1

    Topics: Adult; Amygdala; Anxiety Disorders; Atrophy; Borderline Personality Disorder; Brain Chemistry; Creat

2007
Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.
    Archives of neurology, 2007, Volume: 64, Issue:9

    Topics: Adult; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Aspartic Acid; Atrophy; Biomark

2007
Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure--an in vivo magnetic resonance spectroscopy and imaging study.
    Journal of psychiatric research, 2008, Volume: 42, Issue:11

    Topics: Animals; Aspartic Acid; Atrophy; Choline; Creatine; Dexamethasone; Energy Metabolism; Glucocorticoid

2008
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
    Psychiatry research, 2008, Feb-28, Volume: 162, Issue:2

    Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning,

2008
Neuroimaging findings in hyperargininemia.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2008, Volume: 18, Issue:4

    Topics: Arginine; Aspartic Acid; Atrophy; Basal Ganglia Cerebrovascular Disease; Brain Diseases; Cerebellum;

2008
Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina.
    The New England journal of medicine, 1981, Apr-09, Volume: 304, Issue:15

    Topics: Administration, Oral; Adolescent; Adult; Atrophy; Child; Choroid; Constriction, Pathologic; Creatine

1981
Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia.
    Biochimica et biophysica acta, 1980, Volume: 613, Issue:1

    Topics: Amidinotransferases; Animals; Arginase; Atrophy; Choroid; Creatine; Glycine; Humans; Kidney; Kinetic

1980
Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine.
    The Journal of clinical investigation, 1980, Volume: 66, Issue:4

    Topics: Adolescent; Adult; Amidinotransferases; Arginine; Atrophy; Child; Choroid; Creatine; Female; Glycine

1980
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
    Annals of neurology, 1995, Volume: 37, Issue:2

    Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di

1995
Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy.
    AJNR. American journal of neuroradiology, 1994, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Choline; Creatine; Energy Metabolism; Female; Huma

1994
An investigation of urinary creatine excretion as a potential marker for testicular damage.
    Human & experimental toxicology, 1993, Volume: 12, Issue:2

    Topics: Animals; Atrophy; Biomarkers; Creatine; Creatinine; Ethylene Glycols; Male; Organ Size; Rats; Rats,

1993
Proton magnetic resonance spectroscopic imaging in patients with cerebellar degeneration.
    Annals of neurology, 1996, Volume: 39, Issue:1

    Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Humans; Lac

1996
Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging.
    Radiology, 1997, Volume: 202, Issue:3

    Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Electroencephalography; Epilepsy, Temporal Lobe; F

1997
Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia.
    Diabetes care, 1997, Volume: 20, Issue:6

    Topics: Adult; Aspartic Acid; Atrophy; Blood Glucose; Brain; Cerebral Cortex; Choline; Cognition; Cohort Stu

1997
In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: a preliminary study.
    European journal of medical research, 1997, Nov-28, Volume: 2, Issue:11

    Topics: Adipose Tissue; Adult; Atrophy; Creatine; Dermatomyositis; Female; Humans; Lipid Metabolism; Magneti

1997
Decrease of N-acetylaspartate after ACTH therapy in patients with infantile spasms.
    Neuropediatrics, 1997, Volume: 28, Issue:5

    Topics: Adrenocorticotropic Hormone; Analysis of Variance; Anticonvulsants; Aspartic Acid; Atrophy; Brain; C

1997
MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency.
    AJNR. American journal of neuroradiology, 1998, Volume: 19, Issue:2

    Topics: Amino Acid Metabolism, Inborn Errors; Aspartic Acid; Atrophy; Brain; Brain Diseases, Metabolic; Chil

1998
Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 65, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Aspartic Acid; Atrophy; Brain; CD4

1998
Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy.
    Archives of neurology, 1999, Volume: 56, Issue:3

    Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Case-Control Studies; Cerebral Cortex; Creatine; Female;

1999
Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 1999, Volume: 9, Issue:2

    Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Disease Pro

1999
MR image segmentation and tissue metabolite contrast in 1H spectroscopic imaging of normal and aging brain.
    Magnetic resonance in medicine, 1999, Volume: 41, Issue:4

    Topics: Adult; Age Factors; Aged; Aging; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine;

1999
Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy.
    Annals of neurology, 2000, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Creatine; Dominance, Cerebral; Electroencephalogra

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr

2000
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.
    Archives of neurology, 2001, Volume: 58, Issue:1

    Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Chromatography, High Pressure Liquid; Creatine; Disabil

2001
Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites.
    Investigative radiology, 2001, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine; Female;

2001
Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation.
    Schizophrenia research, 2001, Oct-01, Volume: 52, Issue:1-2

    Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Energy Metabolism; Female; Hu

2001
Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder.
    Biological psychiatry, 2001, Dec-15, Volume: 50, Issue:12

    Topics: Aspartic Acid; Atrophy; Brain; Case-Control Studies; Creatine; Hippocampus; Humans; Magnetic Resonan

2001
Relationship of intracellular creatine concentration and uptake to muscle mass in vivo.
    The American journal of physiology, 1978, Volume: 235, Issue:5

    Topics: Animals; Atrophy; Biological Transport, Active; Creatine; Hypertrophy; Male; Muscle Contraction; Mus

1978
Investigation of stroke in sickle cell disease by 1H nuclear magnetic resonance spectroscopy.
    Neuroradiology, 1992, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Aspartic Acid; Atrophy; Brain; Brain Ischemia; Cerebral Infa

1992
1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders.
    Annals of neurology, 1992, Volume: 31, Issue:2

    Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Child; Creatine; Demyelinating Diseases; Human

1992
Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed beta-guanidinopropionic acid.
    Biochimica et biophysica acta, 1991, Sep-23, Volume: 1097, Issue:2

    Topics: Administration, Oral; Animals; Atrophy; Carcinoma, Ehrlich Tumor; Cell Division; Creatine; Creatinin

1991
Biochemical study of muscle samples from chicken embryos affected by Wofatox 50 EC.
    Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, 1985, Volume: 8

    Topics: Abnormalities, Drug-Induced; Animals; Atrophy; Calcium; Chick Embryo; Cholinesterase Inhibitors; Cre

1985
Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation.
    Ophthalmology, 1985, Volume: 92, Issue:12

    Topics: Adolescent; Adult; Atrophy; Child; Choroid; Creatine; Female; Follow-Up Studies; Humans; Male; Retin

1985
Effects of vitamin E deficiency and high salt supplementation on changes in kidney and testis of rats.
    The Tohoku journal of experimental medicine, 1972, Volume: 106, Issue:4

    Topics: Animals; Atrophy; Body Weight; Creatine; Creatinine; Dietary Fats; Fish Oils; Kidney; Linseed Oil; M

1972
Muscular involvement in rheumatoid arthritis.
    Acta rheumatologica Scandinavica, 1969, Volume: 15, Issue:4

    Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Atrophy; Biopsy; Creatine; Creatine Kinase; Crea

1969